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Summary
Introduction: Internationally the misuse of prescribed medications is becoming a significant public health problem. The 
misuse of opioid analgesics is especially problematic with their use in pregnancy a growing but under reported problem. 
The Case: A male neonate (3.485 kg) suffered poor feeding, gastro-intestinal disturbance, hypoglycaemia, and respira-
tory distress. During pregnancy his mother was prescribed a variety of psychoactive medications including an opiate 
analgesic (co-codamol), an antidepressant (citalopram), an antipsychotic (chlorpromazine) and a benzodiazepine receptor 
agonist (zolpidem). A diagnosis of Neonatal Abstinence Syndrome (NAS) was made following a postnatal disclosure 
of unquantified maternal tramadol misuse in pregnancy. Conclusions: It is important to recognise the risk of prescribed 
medication misuse during pregnancy and the impact these drugs may have on the fetus and neonate. A NAS following 
intrauterine exposure to opioid analgesics has been described clearly in the literature but evidence is limited to case stud-
ies and case series. The management of these neonates should include a full maternal medication history, supported by 
neonatal toxicology, with an applied understanding of the potential neonatal consequences of different intrauterine medi-
cation exposures.
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1. Introduction
The misuse of prescribed drugs is a growing 
problem globally, especially in high income coun-
tries, with the rates of misuse tripling since 1990 [29]. 
Prevalence of prescribed medication misuse is par-
ticularly high in the United States where the rate of 
misuse is predicted to be over four times that seen in 
Europe; in the US the prevalence of prescribed medi-
cation misuse is now second only to cannabis [25]. A 
2012 systematic review observed that the main type 
of medications abused in Europe were analgesics, 
opioid substitution drugs and sedative/hypnotics [4]. 
Internationally prescribed medication and illicit 
drug use in pregnancy is a common but significantly 
under reported occurrence. It is estimated that po-
tentially 40% of women take prescribed medications 
during pregnancy with chronic conditions such as 
depression, hypertension and asthma being the most 
commonly treated [5]. In one European study 1.9% of 
pregnant women declared illicit drug use whilst 3rd 
trimester hair strand analysis identified 16% of wom-
en to be positive for illicit drugs [11]. Alcohol, can-
nabis and prescription opioid analgesics were identi-
fied as the most commonly used drugs in pregnancy 
by one US prospective study with prevalence rates of 
6%, 4% and 3.7% respectively; the detection rates of 
prescription opioids were increased whilst cannabis 
was reduced and alcohol unchanged [19]. Between 
1999 and 2006 in the US fatal poisonings involv-
ing prescription opioid analgesics more than tripled 
[30]. Reflecting both the increase in use of prescribed 
- 6 -
Heroin Addiction and Related Clinical Problems xx(x): xx-xx
medications in pregnancy and the increased rates of 
fatal poisonings is the level of detection of prescribed 
opioids (30% of cases) in post-mortem samples of 
pregnant women with ‘non-natural’ causes of death 
[13]. 
The incidence of depression has been observed 
to be higher within populations of US women receiv-
ing prescriptions for opioid analgesics during preg-
nancy than within the population of women who do 
not [23]. This raises concerns regarding the co pre-
scribing of opioid analgesics and antidepressants dur-
ing pregnancy and the potential for adverse neonatal 
outcomes. The overall absolute risk of NAS second-
ary to prescription opioid exposure during pregnancy 
is predicted to be low (5.9 per 1000 deliveries) but 
increased by the incidental exposure to additional risk 
factors which include psychotropic medication [8]. 
Specifically exposure to selective serotonin reuptake 
inhibitors (SSRIs), cigarettes and cumulative opioid 
exposure are all associated with an increased risk of 
NAS [23]. 
2. The Case
A married multi-parous woman (Gravida 4, Para 
3) of South Asian descent aged 35 years was referred 
to a specialist peri-natal service providing care to 
pregnant substance misusers due to concerns regard-
ing over-use of prescribed co-codamol. The patient 
described episodes of severe anxiety for which she 
would self-medicate with co-codamol due to a belief 
that paracetamol had anxiolytic properties. The pa-
tient reported taking up to eight co-codamol tablets 
(240mg codeine / 4g paracetamol) as a single dose 
during these episodes which would occur several 
times a month. Treatment with co-codamol (30mg 
codeine/500mg paracetamol two tablets QDS) had 
been commenced by the patient’s General Practi-
tioner for the symptom of back pain two years previ-
ously. There was no history of other physical health 
problems; hepatitis and HIV screening were negative. 
There was a history of post-natal depression associ-
ated with her previous pregnancy but no record of 
formal psychiatric assessment or diagnosis. There 
was no history of illicit drug misuse, smoking or al-
cohol consumption. The patient declined ‘agonist 
opioid’ treatment and was subsequently transferred 
onto a prescribed opioid. ICD 10 CM F11.20 (opioid 
dependence, uncomplicated) was diagnosed and the 
patient stabilised and maintained on 180 mg codeine 
daily throughout pregnancy (60mg codeine TDS): 
lower doses resulted in breakthrough back pain; co-
deine phosphate was selected to avoid unnecessary 
paracetamol exposure. Zolpidem (10mg nocte) was 
prescribed for insomnia throughout pregnancy by 
the patient’s General Practitioner. Citalopram (20mg 
OM) and chlorpromazine (25mg TDS) were com-
menced in the third trimester for depression and agi-
tation respectively. Throughout pregnancy maternal 
urine toxicology was positive for opiates only: immu-
noassay testing did not differentiate for codeine. 
A term (40+4) male infant weighing 3.485kg 
(7lb 10oz) was delivered via spontaneous vaginal 
delivery (Apgar scores 9 + 9 at one and nine min-
utes respectively). Difficulty establishing an adequate 
feeding regime was observed from birth with the neo-
nate displaying poor feeding; at 6 hours old he was 
hypoglycaemic (1.7mM/L). Initiation of breast feed-
ing was unsuccessful and neonatal consumption of 
expressed breast-milk was poor (1-2mL of expressed 
breast milk every 3-4 hours) and compounded by 
vomiting. By day 6 the neonate had lost 9% of his 
birth weight and weighed 3.165kg. Thereon weight 
remained stable until day 16 (3.165kg) when it began 
to increase. Gastro-oesophageal reflux was diagnosed 
and thickeners were added to the feeds. Omeprazole 
(0.7mg / kg/ OD dose) was commenced on day 13 
and continued during the first few months of life. 
Problems with reflux persisted until 6 months of age.
On day 2 the neonate became unwell: tem-
perature 37.6°C with signs of respiratory distress. 
A chest x-ray showed ‘streaky shadows on the right 
lower lobe’ and the neonate was transferred to a spe-
cial care facility where antibiotic and fluid therapy 
was commenced for a lower respiratory tract infec-
tion. Blood cultures were negative at 48 hours and 
all bloods including electrolytes and calcium were 
normal. On Day 3 the mother disclosed unquantified 
illicit tramadol use during pregnancy. As a direct con-
sequence of this disclosure the mother was directed to 
stop breast feeding. Neonatal toxicology was positive 
for codeine and morphine (Codeine >500 µg/L and 
Morphine >500 µg/L) consistent with maternal co-
deine therapy. Confirmatory neonatal and /or mater-
nal toxicology for tramadol was not available. NAS 
due to maternal tramadol use was diagnosed using a 
hospital modified version of the Finnegan withdrawal 
scale [10]. An earlier diagnosis of NAS had not been 
considered due to prescribed codeine being within the 
therapeutic range. Treatment with morphine sulphate 
(30 µg/kg 4 hourly) was commenced on day 4 follow-
ing consistent NAS scores >8 and continued at this 
dose for three days. On day 7 it was reduced to 20 
µg/kg 4 hourly for 24 hours then reduced to 10 µg/kg 
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4 hourly from day 8 to day 11. Treatment with mor-
phine sulphate was terminated on Day 11 when NAS 
scores did not exceed 1 in 24 hours. Due to the ma-
ternal history and NAS diagnosis a social work refer-
ral was made. The mother reported no further abuse 
of tramadol postnatally. The neonate was discharged 
home aged 16 days and remains with the family unit. 
Signed patient consent has been obtained for this ar-
ticle.
3. Discussion
NAS is characterised by a collection of behav-
ioural, cardiac and neurological signs reflecting au-
tonomic hyper-stimulation in the neonate typically 
manifesting within 48-72 hours of birth [33]. NAS 
is most frequently associated with intrauterine ex-
posure to heroin or methadone due to maternal use 
during pregnancy. However a ‘neonatal abstinence 
syndrome’ may be a consequence of intrauterine ex-
posure to a wide variety of substances. There is no 
single objective confirmatory diagnostic test for NAS. 
Due to the constellation of clinical signs and symp-
toms that have been associated with the syndrome a 
degree of clinical subjectivity often accompanies di-
agnosis. NAS scoring charts commonly used in the 
assessment of neonates were originally designed for 
the assessment of babies withdrawing from metha-
done. Their validity in the assessment of withdrawal 
from other substances remains untested. 
The quality of evidence regarding neonatal out-
comes following antenatal exposure to psychoactive 
substances is variable and often based on individual 
retrospective case studies and unconfirmed maternal 
histories of drug use. However, there is evidence that 
in-utero exposure to codeine, tramadol, zolpidem, 
citalopram or chlorpromazine may result in a NAS 
in the neonate [12, 14, 17, 21, 22, 26, 28, 31, 32]. 
Symptoms associated with these syndromes are often 
generalised and non-specific. 
Codeine is a short acting opiate which exerts a 
weak analgesic effect at opiate receptors that is en-
hanced by its partial conversion to morphine a pro-
cess heavily dependent upon genetic polymorphisms 
of the CYP2D6 enzyme and is a process that is ob-
served in neonates and children [6, 24]. Several case 
studies have been published detailing retrospective 
diagnoses of NAS based on a maternal history of co-
deine consumption. Onset of symptoms ranged from 
birth to 30 hours post-delivery; vomiting, poor feed-
ing, liquid stools, tremors, irritability, restlessness, 
and seizures were commonly reported symptoms. In 
all cases symptoms improved or resolved following 
treatment with opiates or barbiturates and all were 
symptom free by day 14 [17, 21, 28].
Tramadol is an analgesic acting through mu 
opioid receptors with serotonin and norepinephrine 
reuptake inhibition. Case studies based on retrospec-
tive maternal disclosure of tramadol use during preg-
nancy report irritability, tremulousness, hypertonia, 
tachycardia, vomiting, tachypnoea, high-pitched cry-
ing and disturbed sleep-wake cycle in exposed neo-
nates, commencing between 24-35 hours postnatally 
[14, 22, 32]. In all cases symptoms settled with opi-
ate or CNS depressant treatment and did not reoccur 
again post discharge. 
A neuroleptic discontinuation syndrome in 
adults following cessation of antipsychotic prescrib-
ing is described in the literature [26]. A systematic 
review of antipsychotic therapy during early and late 
pregnancy identified possible perinatal complications 
associated with chlorpromazine therapy in late preg-
nancy: as observed in this case reported symptoms in-
cluded respiratory distress and fever [2]. Nausea and 
vomiting, predominant in this neonate, might also 
occur due to the discontinuation of the anti-emetic 
blockade of dopaminergic receptors.
Zolpidem is a hypnotic benzodiazepine receptor 
agonist (HBRA) that is confirmed to pass across the 
placenta [1]. Evidence regarding the outcomes asso-
ciated with its use in pregnancy are limited. A retro-
spective chart study considered the outcomes of 1979 
neonates exposed to benzodiazepines and/or HBRAs 
during early pregnancy and/or late pregnancy con-
cluding first trimester exposure increased risk of neo-
natal hypoglycaemia whilst late exposure was associ-
ated with an increased risk of respiratory problems 
[31]. For clarity the clinical presentation in this case 
is recorded against the symptomatology described in 
the literature (Table 1). 
Consequences of antenatal exposure to antide-
pressants has been investigated more extensively. A 
systematic review identified one meta-analysis and 
fourteen other controlled studies showing an associa-
tion between gestational exposure to antidepressants 
and neonatal adaptation difficulties [27]. Neonatal 
respiratory distress was a frequently reported prob-
lem in affected infants. Other neonatal problems 
described included gastrointestinal and feeding dis-
turbances and metabolic disorders including hypo-
glycaemia. A study considering 1602 infants who 
had been exposed to SSRIs in utero identified third 
trimester exposure to be associated with various neo-
natal problems including hypoglycaemia, respiratory 
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distress syndrome, and temperature regulation disor-
ders [7]. 
In this case a diagnosis of NAS was not con-
sidered by the paediatric carers until the maternal 
disclosure of unconfirmed tramadol misuse dur-
ing pregnancy on postnatal Day 3. It was following 
this maternal disclosure that a decision was made to 
stop breast feeding. Paediatricians felt there was in-
sufficient information regarding the implications of 
breastfeeding with potential ongoing maternal trama-
dol misuse and polypharmacy to advocate this inter-
vention and a review of the literature supports this [3]. 
Antidepressants are excreted into breast milk at low 
levels and a consensus exists that most are generally 
safe in breastfeeding [2]. Data informing the safety 
profiles of antipsychotic medications in breastfeeding 
is limited to only a few prospective and case studies 
detailing the outcomes of only a few neonates [18]. 
Direct data from studies examining the safety profile 
of BDRAs in breastfeeding is very limited whilst the 
safety of benzodiazepines in breastfeeding, especially 
at lower doses, seems to be established [16]. Care is 
required with breastfeeding in the presence of mater-
nal codeine use as neonatal deaths and over-sedation 
have been observed due to the inter-individual varia-
tions in maternal codeine metabolism [20]. In cases 
of maternal psychoactive polypharmacy breastfeed-
ing may have a role in attenuating the duration and 
severity of NAS in the neonate and it may be appro-
priate to consider encouraging breastfeeding as part 
of a care plan in these cases [9].
4. Conclusions 
In this case predominant NAS symptoms were 
hypoglycaemia, poor feeding, gastrointestinal distur-
bance, and respiratory distress and it is only possible 
to speculate how the medications prescribed in preg-
nancy may have contributed to this presentation. It is 
likely that codeine combined with tramadol use during 
pregnancy contributed to NAS postnatally. Perinatal 
care providers need to be sensitive to the potential of 
neonatal complications following intrauterine expo-
sure to commonly prescribed analgesics even within 
therapeutic doses. With the international increase in 
misuse of prescription opioids it is likely that in the 
future many more affected neonates will be identified 
and robust neonatal care pathways need to be imple-
mented. More robust research detailing the outcomes 
of neonatal and child exposures to opioid analgesics 
and other psychoactive medications is called for: in 
particular cumulative effects of co-prescribed medi-
cations should be considered. The absence of specific 
screening tools and diagnostic testing protocols may 
hamper the diagnosis of NAS in exposed neonates 
and may lead to misdiagnosis or delayed diagnosis. 
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